key: cord-0252272-wjb709xa
authors: Amirsavadkouhi, Ali; Shahrami, Reza; Zadeh, Nadia Mohammad; Ilkhani, Saba; Mirtajani, Seyed Bashir; Salimi, Vahid; Mahjoubifard, Maziar; Jahangirifard, Alireza
title: Effects of Morphine and Fentanyl on Patients with COVID-19
date: 2021-02-03
journal: Tanaffos
DOI: nan
sha: de6052579ce0f5c13139be8645f5fd9b70259193
doc_id: 252272
cord_uid: wjb709xa

BACKGROUND: Sustained inflammation has been observed in the majority of severe COVID-19 cases. The impact of choice of opioid on perioperative inflammatory processes has not been assessed in the clinical setting. MATERIALS AND METHODS: Patients with novel coronavirus (COVID-19) who referred to Masih Daneshvari and Noor-Afshar Hospitals in Tehran were included in the study after providing full explanations and obtaining written consent. Patients were then randomly divided into three groups: morphine, fentanyl and control. Patients in the morphine group received 3 mg of morphine intravenously every 6 hours for 5 days, whereas in the fentanyl group, 1.5 mcg / kg / h of fentanyl was infused for 2 hours on 5 consecutive days. The results were evaluated based on the design of the questionnaire and its completion using t-test and SPSS25 software. RESULTS: A total of 127 participants responded to the survey between 20 April and 20 June 2020, of whom 90 (70.86%) with the average age 65.2 years, provided complete data on variables included in the present analyses. 53 (58.33%) of all individuals were men and 37 (41.12%) were women. Accordingly, 22 (24.4%) patients had a history of hypertension. However, diabetes with 16 (17.77%) cases and kidney diseases with 12 (13.33%), were the next most common underlying diseases. Evaluation of patients' clinical, laboratory and inflammatory conditions at different time intervals in both fentanyl and morphine groups did not show significant changes between these groups and the patients in the control one. CONCLUSION: The results of this study did not show any significant change in the use of fentanyl and morphine compared to patients with COVID 19. This may be due to the use of these drugs in the viral phase of the disease. The use of morphine and fentanyl in the viral phase of COVID 19 disease do not show significant benefits.

Cytokine storm has been observed in the majority of severe COVID-19 cases (1, 2) . High concentrations of cytokines such as IL-2, IL-7, IL-10, G-SCF, IP10, MCP1, MIP1A, and TNF-α were recorded in plasma of critically ill patients infected with SARS-CoV-2, indicating that the cytokine storm could be associated with disease severity (3) . Due to the fact that intensive inflammation leads to diseaseinduced morbidity and mortality, using anti-inflammatory agents may provide a new relevant strategy (4) . Infection is TANAFFOS Amirsavadkouhi A, et al. 165 Tanaffos 2021; 20 (2) : [164] [165] [166] [167] [168] [169] [170] [171] regulated by multiple cytokines that act in concert to proceed inflammatory responses (5, 6) .

Opioid/cannabinoid receptors-based drugs can modulate immune cell migration and cytokine/chemokine secretion, and represent a promising pharmacological platform for developing anti-inflammatory therapeutics (7) .

Opium is one of the strongest analgesics used for the treatment and control of pain (8) . Numerous studies have examined the relationship between innate and drugcompatible immune cells in vitro, in vivo, and epidemiological and clinical studies in different patient groups (9) (10) (11) (12) . Laboratory studies in animals have shown that opium suppresses the immune system in the body (13) . Also, physicians in the past used anodynes of opium tincture as a treatment of "bronchitis" and other ailments in infants and children, as case reports and experience "demonstrated the efficacy" of the concoction in controlling coughing and facilitating breathing.

Morphine is a member of morphinone-shaped alkaloids found in the poppy plant (14) , which is a potent agonist of opioid receptors that acts on three types of receptors, causing effects that are mainly at the supraspinal and spinal level. Research on the antiviral properties and effects of this drug has shown its beneficial effects in the treatment of viruses such as SHV-1 (15) . However, some studies have shown evidence of suppression of immunological factors with the use of morphine (16) .

Fentanyl, also is synthetic opioid used as a pain medication (17) . Fentanyl works primarily by activating μ-opioid receptors (18) . It is around 100 times stronger than morphine, and some analogues such as carfentanil are around 10,000 times stronger (19) .

Opioids interfere with the immune system in a number of ways, including some components involved in the immune response, such as granulocytes and macrophages (20) . A large source of endogenous opioids is inflammatory tissues of immune cells. In addition to its analgesic effects, morphine also has some anti-inflammatory effects. Examination of patients' laboratory conditions (Table 3) at different time intervals in the two groups of fentanyl and morphine did not show significant changes between the two groups of patients.

The results in Figure 2 show that the use of morphine and fentanyl could not significantly change the inflammatory parameters of patients. In this study the effect of morphine and fentanyl on the renal or hepatic functional parameters was not considerable. However, some studies have shown that the use of opioids can lead to remarkable changes in the level of these factors (41, 42) . According to our knowledge, patients with COVID-19 have an inflammatory attack that is known to be the main cause of damage to these organs (not hemodynamic problems and underlying diseases), and because the studied drugs could not justify the inflammatory response, the results seems to be logical.

Because of some restrictions, assessment of cytokines, interleukins, and other biomarkers involved in inflammation and viral infections was not possible, so measuring these factors can lead to more favorable results.

Also, conducting a study with the approach of examining patients in the inflammatory phase and using different doses of opium (with emphasis on the increasing dose) may achieve different results.

The use of morphine and fentanyl in the viral phase of COVID 19 disease is not associated with significant changes in the clinical, laboratory and inflammatory factors in patients with mild-moderate symptoms.

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan, China

Can Hesperidin be the Key to the Treatment of Severe 170 Opium and COVID-19

Acute Respiratory Syndrome COV-2?

Teicoplanin: an alternative drug for the treatment of COVID-19?

Pattern of early human-to-human transmission of Wuhan

Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model

The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system

Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study

Disease-Induced Skeletal Muscle Atrophy and Fatigue

microRNA regulation of inflammatory responses

Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients

Goodman and Gilman's the Pharmacological Basis of Therapeutics

Human iPSC-Derived Blood-Brain Barrier Models: Valuable Tools for Preclinical Drug Discovery and Development?

The exciting future of antifungal therapy

Functional selective FPR1 signaling in favor of an activation of the neutrophil superoxide generating NOX2 complex

COVID-19-Related severe heterogeneous acute respiratory distress syndrome: A therapeutic challenge

Opiates, stress, and immunity: Animal studies

Morphine-6-glucuronide, a potent mu agonist

Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat

Morphine metabolites

Opioids, opioid receptors, and the immune response

Pharmacological effects of compounds from echinoderms

Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review

Misuse of Novel Synthetic Opioids: A Deadly New Trend

A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome

Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report

Prominent coagulation disorder is closely related to inflammatory response and could be as a prognostic indicator for ICU patients with COVID-19

Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic

COVID-19, SARS and MERS: are they closely related?

Selective suppression of microglial activation by paeoniflorin attenuates morphine tolerance

Central aortic pressure monitoring using a brachial artery line: is it ready for use in cardiac surgery?

Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations

Microglia-mediated neurotoxicity is inhibited by morphine through an opioid receptor-independent reduction of NADPH oxidase activity

Bilateral central retinal artery occlusion (CRAO) after opium consumption

Effect of opium addiction on new and traditional cardiovascular risk factors: do duration of addiction and route of administration matter?

NRITLD Protocol for the Management of Patients with COVID-19 Admitted to Hospitals

The Effects of Opium Addiction on the Immune System Function in Patients with Fungal Infection

Immunomodulation in the critically ill

Opioids Resistance in Chronic Pain Management

The effects of opioids on the lung

Opioids and renal function

Opioid complications and side effects